Liver Ablative Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM)

Stereotactic Ablative Body Radiotherapy (SABR) is an established treatment for both primary and secondary liver malignancies and is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of Kilovoltage Intrafraction Monitoring (KIM) as a potential solution for real-time image guidance in liver SABR. It is hoped that this information will improve cancer targeting accuracy and lead to better patient outcomes in the future.

Primary Sponsor

University of Sydney

Collaborating Groups

TROG Cancer Research

Accrual Target

46

Closing Date of Accrual

11 December 2023

Trial Chairperson

Dr Yoo Young (Dominique) Lee, Princess Alexandra Hospital, QLD
Dr Tim Wang, Crown Princess Mary Cancer Centre, Westmead, NSW

Trial Contact

LARK@trog.com.au

Clinical Trial Registration

Related Post

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

Grant for PRIME-Lung trial
10 June, 2025

MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer

LATEST NEWS: 10 JUNE 2025 A trial of a